Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?

Diabetes Res Clin Pract. 2023 Apr:198:110624. doi: 10.1016/j.diabres.2023.110624. Epub 2023 Mar 9.

Authors

M Gallo¹, M Monami², A Ragni³, V Renzelli⁴

Affiliations

¹ Endocrinology and Metabolic Diseases Unit, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. Electronic address: marco.gallo@ospedale.al.it.
² Diabetology, Careggi Hospital and University of Florence, Italy.
³ Endocrinology and Metabolic Diseases Unit, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
⁴ Diabetologist and Endocrinologist, Italian Association of Clinical Diabetologists, Rome, Italy.

PMID: 36906235
DOI: 10.1016/j.diabres.2023.110624

No abstract available

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / adverse effects
Neoplasms*
Sodium-Glucose Transporter 2

Substances

Sodium-Glucose Transporter 2
Hypoglycemic Agents
Glucagon-Like Peptide-1 Receptor